Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06739278

Enrollment

119

Registered

2024-12-18

Start date

2024-12-20

Completion date

2025-01-31

Last updated

2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Brief summary

This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.

Detailed description

Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

* Clinical diagnosis of Perianal Fistulizing Crohn's Disease * Receive ustekinumab therapy

Exclusion criteria

* Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs * Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc. * Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc. * Combined with malignant tumor * Clinical data missing ≥30% or no follow-up

Design outcomes

Primary

Measure	Time frame
imaging remission rate of anal fistula	Treatment week 0 to 32

Countries

China

Contacts

Primary ContactYi Jiang

1009419972@qq.com+86-13676715543

Backup ContactLuyan Fang

239542008@qq.com+86 13806552632

Outcome results